Phase II Single Arm Study to Assess Dinutuximab (Ch 14.18) Combined With the Cytokines Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) and IL-2 in Patients With High-risk Neuroblastoma Not Eligible to Other Immunotherapy Trials
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Dinutuximab (Primary) ; Interleukin-2; Isotretinoin; Sargramostim
- Indications Neuroblastoma
- Focus Adverse reactions
- 08 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Oct 2016 Planned number of patients changed from 10 to 25.
- 13 Oct 2016 Planned End Date changed from 1 May 2017 to 1 May 2019.